Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03982693 · ClinicalTrials.gov registry record · Phase 3
Trial to Assess Chelation Therapy in Critical Limb Ischemia
A Phase 3 study of Diabetes and Critical Limb Ischemia, sponsored by Mt. Sinai Medical Center, Miami.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03982693 is a Phase 3 study of Diabetes and Critical Limb Ischemia that is actively recruiting participants, run by Mt. Sinai Medical Center, Miami. The registered enrollment target is 50 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03982693, a Phase 3 study of Diabetes and Critical Limb Ischemia, is actively recruiting participants, sponsored by Mt. Sinai Medical Center, Miami.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Edetate Disodium
Study Locations (1)
Florida
- Mount Sinai Medical Center - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2025-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03982693
The ClinicalTrials.gov registry entry for NCT03982693 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is Mt. Sinai Medical Center, Miami, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03982693 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03982693 about?
NCT03982693 is a clinical study titled "Trial to Assess Chelation Therapy in Critical Limb Ischemia". TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.
What is the current status of trial NCT03982693?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2019-03-19. Estimated completion is 2025-07.
What conditions does trial NCT03982693 study?
This clinical trial studies the following conditions: Diabetes, Critical Limb Ischemia.
What interventions are being tested in trial NCT03982693?
The interventions under investigation include: Placebo (OTHER), Edetate Disodium (DRUG).
Who is sponsoring clinical trial NCT03982693?
This trial is sponsored by Mt. Sinai Medical Center, Miami, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03982693 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
COMPLETED · Phase 3
-
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
COMPLETED · Phase 3
-
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
COMPLETED · Phase 3
-
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
-
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.